source
- J&J advances IBD combo to Phase 3 despite Phase 2 setbacksJohnson & Johnson said it will advance its experimental inflammatory bowel disease therapy, JNJ-4804, into Phase 3 trials even though the drug failed to meet primary endpoints in two Phase 2 studie…
- STAT+ examines AI diagnostic claims, telehealth abortion access and Epic lawsuit in latest health tech newsletterSTAT+ published a health‑tech newsletter that asks whether artificial intelligence has truly outperformed physicians in diagnosing disease, citing a high‑profile study on AI diagnostic performance.…